Table 2.
The summarize of treatment doses and toxicities for the 14 patients received crizotinib treatment after acquired resistance to first generation EGFR-TKI
| Patient no. | Age/gender | EGFR mutataion | Treatment after acquired resistance | Grade 3–4 toxicities | Reduce dose |
|---|---|---|---|---|---|
| 1 | 55/male | 21L858R | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
| 2 | 65/female | 21L858R | Gefitinib 250 mg/qd + crizotinib 250 mg/bid | Aminotransferase rise | Gefitinib 250 mg/qd + crizotinib 200 mg/bid |
| 3 | 53/male | 21L858R | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
| 4 | 49/male | 21L858R | Gefitinib 250 mg/qd + crizotinib 250 mg/bid | No | No |
| 5 | 62/female | 21L858R | Elotinib 150 mg/qd + crizotinib 250 mg/bid | Aminotransferase rise | Elotinib 150 mg/qd + crizotinib 200 mg/bid |
| 6 | 60/female | 19 exon deletion | Icotinib 125 mg/tid + crizotinib 250 mg/bid | No | No |
| 7 | 37/male | 19 exon deletion | Crizotinib 250 mg/bid | No | No |
| 8 | 64/male | 21L858R | Crizotinib 250 mg/bid | No | No |
| 9 | 71/female | 21L858R | Crizotinib 250 mg/bid | Nausea | Crizotinib 200 mg/bid |
| 10 | 64/female | 21L858R | Crizotinib 250 mg/bid | No | No |
| 11 | 58/male | 21L858R | Crizotinib 250 mg/bid | No | No |
| 12 | 41/female | 21L858R | Crizotinib 250 mg/bid | No | No |
| 13 | 58/female | 21L858R | Crizotinib 250 mg/bid | No | No |
| 14 | 53/female | 21L858R | Crizotinib 250 mg/bid | No | No |